19 results on '"Ribalov, Rinat"'
Search Results
2. Healthcare utilization, costs, and epidemiology of Huntington’s disease in Israel
3. Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting
4. Defining Utility Values for Chorea Health States in Patients with Huntington’s Disease
5. The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data (P1-11.012)
6. Chorea Severity Change Over Time in Huntington Disease and by Huntington Disease Stage (P1-11.010)
7. Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity (P2-11.011)
8. Burden of migraine in Brazil: A cross‐sectional real‐world study
9. The Clinical and Economic Burden of Tardive Dyskinesia in Israel
10. Prescription Opioids in Patients With Migraine in Southern Israel: a Retrospective Database Analysis (P17-2.001)
11. Direct Health Care Costs of Patients Suffering With Migraine in Southern Israel: a Retrospective Database Analysis (P17-2.006)
12. Migraine Epidemiology in Southern Israel: A Retrospective Database Study (P17-2.004)
13. Defining utility values for patients with tardive dyskinesia
14. Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
15. Real-world incidence and costs of serious infections and cardiovascular complications among patients with indolent non-Hodgkin lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
16. Defining Utility Values for Chorea Health States in Patients With Huntington’s Disease (4360)
17. Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
18. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113
19. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.